Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175298 | 0.90 | SRC (0.42) | CFTRLRRK2RIPK2SRCLCK | |
| SCHEMBL20173314 | 0.83 | CFTR (0.40) | CFTRNOTUMEIF2AK3SRCIRAK4 | |
| SCHEMBL20173318 | 0.82 | TEK (0.41) | CFTRRIPK2EIF2AK3SRCLCK | |
| SCHEMBL20181897 | 0.80 | SRC (0.42) | CFTRNOTUMRIPK2EIF2AK3SRC | |
| SCHEMBL20173321 | 0.80 | SRC (0.52) | NOTUMRIPK2SRCLCKKDR | |
| SCHEMBL20182215 | 0.80 | NOTUM (0.48) | CFTRNOTUMPTGS2CA2CA4 | |
| SCHEMBL21187310 | 0.79 | CFTR (0.46) | CFTRNOTUMSRCLCKRET | |
| SCHEMBL30037245 | 0.79 | CFTR (0.41) | CFTRNOTUMRIPK2EIF2AK3SRC | |
| SCHEMBL20162676 | 0.79 | CFTR (0.41) | CFTRNOTUMRIPK2EIF2AK3SRC | |
| SCHEMBL23481428 | 0.77 | EIF2AK3 (0.41) | CFTRNOTUMRIPK2EIF2AK3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CFTR 1/4885LRRK2 1435/4885NOTUM 3642/4885 |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | CFTR 1/4885LRRK2 1373/4885NOTUM 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.